Understanding the Early Signs of Memory Loss in Individuals at Risk for Alzheimer’s Disease

Understanding Early Memory Loss in Alzheimer’s Disease

Research Focus

A team of researchers investigated individuals with a genetic predisposition to Alzheimer’s disease to determine when memory loss begins. Alzheimer’s disease is a neurological disorder characterized by the gradual degeneration of nerve cells, leading to dementia. Memory impairment is one of the earliest signs of this condition, particularly affecting the medial temporal lobe, a brain region crucial for memory function. However, cognitive decline may start before any prominent clinical symptoms are evident, suggesting that Alzheimer’s is often diagnosed only after subtle signs have persisted for a while.

Genetic Factors in Alzheimer’s Disease

While most Alzheimer’s cases are sporadic and occur without a family history, some are inherited and can be predicted through genetic testing for specific mutations. The two forms of the disease share many similarities, and the age of onset for those with autosomal dominant mutations can often be accurately predicted based on family history. This aspect makes cases of autosomal dominant Alzheimer’s particularly valuable for understanding cognitive changes that occur in the years prior to the disease’s onset.

Study on Accelerated Long-Term Forgetting

Research Overview

A recent study published in Lancet Neurology by researchers from several UK universities focused on accelerated long-term forgetting in individuals genetically linked to Alzheimer’s disease. Accelerated long-term forgetting refers to the ability to recall information correctly in the short term (e.g., 30 minutes) but experiencing significant difficulty in long-term recall (e.g., after a week). Most memory assessments are conducted over short intervals, which can mask early cognitive decline.

Study Design and Methodology

The study recruited participants already involved in a long-term study of familial Alzheimer’s disease at University College London. The subjects had an affected parent, giving them a 50% chance of carrying the Alzheimer’s mutation. At the time of the study, none exhibited any signs or symptoms of the disease, being approximately seven years away from the expected age of onset. Of the 35 participants, 9 had previously undergone genetic testing and were aware of their status.

Researchers conducted genetic testing on the remaining participants without revealing results prior to the study, dividing them into two groups: mutation carriers and controls. The participants underwent three tests:

1. Recall of a 15-item word list
2. A short story
3. A complex visual figure

Findings on Memory Recall

Participants were assessed for recall after 30 minutes and again after seven days. The 30-minute test was conducted immediately, while the seven-day assessment was done remotely and without prior notice of the content. Although no significant differences arose between the groups after the 30-minute test, the carrier group exhibited poorer memory scores after the seven-day interval. This finding indicates that even without obvious clinical symptoms, individuals with a genetic predisposition to Alzheimer’s may experience cognitive decline.

Implications and Limitations

The study highlighted limitations, including a small sample size and the inability to account for participants’ sleep patterns during the seven-day gap, which may have influenced memory performance. Nevertheless, the research offers valuable insights into how episodic memory impairment may occur before other Alzheimer’s symptoms become apparent. Accelerated long-term forgetting appears to be one of the earliest detectable features of Alzheimer’s disease progression.

Conclusion

This research underscores the importance of monitoring memory recall in individuals at risk for Alzheimer’s disease, as it may help in identifying cognitive decline early and assessing the effectiveness of potential preventative treatments for asymptomatic individuals.

Reference

Weston JS et al. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol. 2018; 17:123-32.